Back to Stakeholders

Global HEOR professional society with major U.S. footprint and an evidence dissemination platform that includes psychedelic-adjacent esketamine budget-impact analyses.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

Health Economics Research Group

Jurisdiction

Global

Coverage

Global

Last Verified

Apr 11, 2026

Focus Areas

Cost-Effectiveness ModelingBudget Impact AnalysisHTA Evidence Appraisal

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget Impact

Market Access Notes

ISPOR presentation resources include U.S. budget-impact work on esketamine for treatment-resistant depression, making it directly relevant for psychedelic-adjacent market-access evidence.

Verification

Verified

Psychedelic Focus

Explicit Psychedelic Focus

Engagement Status

Active

Primary Access Link

Quick Facts

Website
Visit